Since efficient retargeting of primary NK cells was achieved, the authors provided the background to justify clinical translation of this GPC3-specific NK cell-based therapeutic as a novel treatment option for patients with GPC3+ HCC [142]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.